Cizzle Biotechnology Secures US Patent to Advance Lung Cancer Diagnostic Technology

Cizzle Biotechnology (LSE:CIZ) has achieved a significant milestone by securing a United States patent for its lung cancer detection technology. The patent specifically covers methods for detecting a variant of the CIZ1B biomarker, which forms the basis of the company’s diagnostic platform aimed at earlier identification of lung cancer.

This newly granted patent bolsters Cizzle Biotechnology’s intellectual property protection in one of the world’s most influential healthcare markets. It adds exclusivity to the company’s proprietary technology, supporting future commercialization and licensing opportunities within healthcare systems and laboratory networks across North America.

The CIZ1B biomarker test is designed to detect biological indicators associated with lung cancer, offering a potential tool to aid healthcare professionals in identifying patients who may require further diagnostic investigation. Early detection of lung cancer is critical, as treatment outcomes are generally more favorable when the disease is diagnosed at an earlier stage.

Traditional diagnostic pathways for lung cancer often involve multiple assessments and imaging procedures, which can delay diagnosis. Biomarker-based testing, such as that developed by Cizzle Biotechnology, aims to complement existing methods by providing additional, non-invasive means to detect early disease signals.

The importance of patent protection in biotechnology cannot be overstated. It safeguards scientific innovation, provides commercial advantages, and facilitates strategic partnerships. By securing this US patent, Cizzle Biotechnology strengthens its position within the growing diagnostics sector and enhances its ability to expand its lung cancer testing portfolio.

This development follows the company’s broader strategy to grow its intellectual property portfolio and expand its commercial footprint across North America. The patent grant is expected to support ongoing efforts to bring the CIZ1B lung cancer biomarker test to a wider market, addressing a critical unmet need in early lung cancer detection.

Lung cancer remains one of the most serious health challenges globally, with early diagnosis recognized as a key factor in improving patient outcomes. Innovations like Cizzle Biotechnology’s biomarker technology are attracting increasing attention from the medical community for their potential to transform diagnostic pathways.

The company’s latest patent adds to a growing collection of intellectual property protections, reinforcing its commitment to advancing lung cancer diagnostics through scientific innovation and strategic market expansion.